STEPHEN PRAY: Open Payments
NPI 1114199759 · CHANDLER, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$849 in 18 payments from 8 companies in 2025. Trend: 2023 $623 · 2024 $696 · 2025 $849
Food & beverage: $849
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 7 | $441 |
| E.R. Squibb & Sons, L.L.C. | 2 | $147 |
| Janssen Pharmaceuticals, Inc | 2 | $88 |
| Otsuka America Pharmaceutical, Inc. | 2 | $53 |
| Alkermes, Inc. | 2 | $50 |
| Indivior Inc. | 1 | $37 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
| Neurocrine BioSciences, Inc. | 1 | $15 |
Products named: UZEDY, COBENFY, SPRAVATO, SUBLOCADE, ABILIFY ASIMTUFII, LYBALVI, ABILIFY MAINTENA, INVEGA SUSTENNA.
Industry payments across AZ — which companies pay providers there.
